And the reason they excluded people that have previously used an EGFr inhibitor is because the tumors build up a tolerance to EGFr inhibitors as my wide did. (in combination with Irinotecan and Avastin). However as they have found many times a tumor will again become sensitive to EGFr treatment after a period of time without being treated with an EGFr inhibitor. Apparently the tumors would rather revert back to the EGFr pathway than the alternative ERbb2, 3 and 4 pathways it uses to get around the EGFr pathway blockade. I wish I could find that publication again.
Good luck guys.... Wish I knew about this one and that it were local to us before my wife did the Irrinotecan, Erbitux, Avastin trial.
DW 53 dx Jun 13
CT mets Liver Spleen lung. IVb CEA~110
Jul13 Sig Resct
8/13 FolFox + Avastin 12Tx mild sfx
Ongoing 5-FU Avastin every 3 wks.
CEA: 9/23/13 53 10/21/13 22 12/2/13 8 1/13/14 3.7 8/12/14 2.3 7/2/15 4.0 8/21/15 5.9
7/7/14 CT Can't see the spleen Mets Stable until... CEA up
8/16/15 CT new abdominal spots. Now Iri, 5-FU, Avastin every other week.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen